Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis.

Yi YangXiao HeRongseng ZhaoWei GuoMing ZhuWei XingDongpo JiangChongyang LiuXiang Xu

Published in: Journal of translational medicine (2018)

Allogeneic MSCT is safe and feasible, and we propose high serum IFN-γ levels as a potent biomarker for predicting MSCT response. Trial registration chictr.org, ChiCTR-ONC-16008770. Registered 3 July 2016, http://www.chictr.org.cn/showproj.aspx?proj=14820.

Keyphrases

rheumatoid arthritis
bone marrow
mesenchymal stem cells
dendritic cells
immune response
stem cell transplantation
study protocol
clinical trial
cell therapy
disease activity
lymph node metastasis
stem cells
phase iii
phase ii
squamous cell carcinoma
umbilical cord
low dose
systemic sclerosis